Development and Validation of a Highly Sensitive and Rapid LC-MS3 Strategy to Determine Oxcarbazepine and Its Active Metabolite in the Serum of Patients with Epilepsy and Its Application in Therapeutic Drug Monitoring
Abstract
Share and Cite
Ji, Z.; Li, T.; Zhao, X.; Ma, W.; Li, Y.; Huang, J. Development and Validation of a Highly Sensitive and Rapid LC-MS3 Strategy to Determine Oxcarbazepine and Its Active Metabolite in the Serum of Patients with Epilepsy and Its Application in Therapeutic Drug Monitoring. Molecules 2022, 27, 5670. https://doi.org/10.3390/molecules27175670
Ji Z, Li T, Zhao X, Ma W, Li Y, Huang J. Development and Validation of a Highly Sensitive and Rapid LC-MS3 Strategy to Determine Oxcarbazepine and Its Active Metabolite in the Serum of Patients with Epilepsy and Its Application in Therapeutic Drug Monitoring. Molecules. 2022; 27(17):5670. https://doi.org/10.3390/molecules27175670
Chicago/Turabian StyleJi, Zhengchao, Tingting Li, Xin Zhao, Wei Ma, Yanyan Li, and Jing Huang. 2022. "Development and Validation of a Highly Sensitive and Rapid LC-MS3 Strategy to Determine Oxcarbazepine and Its Active Metabolite in the Serum of Patients with Epilepsy and Its Application in Therapeutic Drug Monitoring" Molecules 27, no. 17: 5670. https://doi.org/10.3390/molecules27175670
APA StyleJi, Z., Li, T., Zhao, X., Ma, W., Li, Y., & Huang, J. (2022). Development and Validation of a Highly Sensitive and Rapid LC-MS3 Strategy to Determine Oxcarbazepine and Its Active Metabolite in the Serum of Patients with Epilepsy and Its Application in Therapeutic Drug Monitoring. Molecules, 27(17), 5670. https://doi.org/10.3390/molecules27175670
